[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolic-cardiomyopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolic-cardiomyopathy":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100489526","development-of-circ-technologies-100489526",false,"NCT05654272","Development of CIRC Technologies","Development of Cardiovascular Innovation Research Technologies","CIRC","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Provision of written informed consent\n* If not healthy volunteer, must be diagnosed with cardiovascular disease\n\nExclusion Criteria:\n\n* Vulnerable populations will be excluded from this study including Prisoners\n* Other contraindications to CMR imaging to be determined by standard MRI protocols\n* Decisionally impaired (e.g., dementia or cognitive disability)",true,"ALL","18 Years",{"count":21,"type":22},1000,"ESTIMATED","20 Years","OBSERVATIONAL","Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which markers are the most sensitive. This multi-study will allow us the unique opportunity to form a more comprehensive understanding for various cardiovascular diseases.\n\nOur team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotypes including myocardial inflammation, fibrosis, metabolism, and microstructural defects. Among these phenotypes, myocardial microstructure has proven to be most sensitive to early myocardial tissue damage and is predictive of myocardial regeneration. In this study, the investigators aim to further study the importance of cardiac microstructure revealed by MRI in patient and healthy population and compare this novel technology with conventional clinical biomarkers.",[27,28,29,30,31,32,33,34,35,36],"Cardiovascular Diseases","Heart Failure","Ischemic Heart Disease","Non-ischemic Cardiomyopathy","Valvular Heart Disease","Metabolic Cardiomyopathy","Congenital Heart Disease","Aortic Diseases","Atrial Fibrillation","Ventricular Fibrillation",[38],"MRI","RECRUITING","2026-05-06",{"date":42,"type":43},"2026-05-08","ACTUAL",{"date":45,"type":43},"2022-09-09",{"date":47,"type":22},"2042-09-09",{"name":49,"class":50},"The Cleveland Clinic","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100599224","longitudinal-validation-of-circ-technologies-100599224","NCT07081711","Longitudinal Validation of CIRC Technologies","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Vulnerable populations will be excluded from this study including Prisoners\n* Other contraindications to CMR imaging to be determined by standard MRI protocols\n* Decisionally impaired (e.g., dementia or cognitive disability)",{"count":21,"type":22},"Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which markers are the most sensitive. This multi-study will allow the unique opportunity to form a more comprehensive understanding for various cardiovascular diseases.\n\nThe study team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotypes including myocardial inflammation, fibrosis, metabolism, and microstructural defects. Among these phenotypes, myocardial microstructure has proven to be most sensitive to early myocardial tissue damage and is predictive of myocardial regeneration. In this study, the investigators aim to further study the importance of cardiac microstructure revealed by MRI in patient and healthy population and compare this novel technology with conventional clinical biomarkers.",[27,28,29,30,31,32,33,34,35,36],[38],"NOT_YET_RECRUITING","2026-03-19",{"date":65,"type":43},"2026-03-23",{"date":67,"type":22},"2026-04",{"date":69,"type":22},"2037-08",{"name":49,"class":50},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":51},"100577162","early-identification-and-treatment-of-rare-cardiomyopathy-cohorts-100577162","NCT06794710","Early Identification and Treatment of Rare Cardiomyopathy Cohorts","Early Identification and Treatment of Rare Myocardium by Multimodal Imaging (EARLY-MYO-RARE)","EARLY-MYO-RARE","Inclusion Criteria:\n\n* Age 18-75 years old.\n* Patients preliminarily diagnosed with heart failure and scheduled to receive drug therapy after being evaluated by cardiology departments.\n* No history of structural heart disease, and the Framingham score \\<5 (for patients with the Framingham score ≥5, coronary artery disease will be excluded by coronary angiography\u002Fcoronary CT\u002Fexercise platelet).\n* Creatinine clearance ≥50ml\u002Fmin (Cockcroft-Gault formula).\n* LVEF ≥50% assessed by Echocardiography.\n* QT interval \\< 470 ms.\n* Providing written informed consent.\n\nExclusion Criteria:\n\n* Presence of acute\u002Fchronic renal impairment (GFR \\<50\u002Fml\u002Fmin\u002F1.73m2).\n* History of cardiovascular disease such as confirmed coronary artery disease, valvular disease, cardiomyopathy, congenital heart disease, and heart failure.\n* Presence of contraindications to CMR.","75 Years",{"count":81,"type":22},300,"INTERVENTIONAL",[84],"NA","This study aims to further develop an imaging-guided cohort of rare cardiomyopathies based on the existing database. The investigators will standardize the construction of a cohort that integrates a clinical data repository, serum biobank, myocardial tissue bank, and imaging database. In the current cohort, the investigators will systematically screen for biomarkers indicative of pathological changes in challenging cardiomyopathies. Multidimensional data will be integrated to establish and optimize a heart failure risk assessment model, which will then be validated in a prospective cohort. The effectiveness of the model in assessing different risk groups will be evaluated, with the goal of achieving precise prevention of heart failure from the source.",[87,88,32,89],"Hypertrophic Cardiomyopathy (HCM)","Dilated Cardiomyopathy (DCM)","Restrictive Cardiomyopathy",[91],"rare cardiomyopathy, cardiac multimodal imaging, myocardial impairment","2025-01-21",{"date":94,"type":43},"2025-01-27",{"date":96,"type":22},"2025-02-01",{"date":98,"type":22},"2027-09-30",{"name":100,"class":50},"RenJi Hospital"]